Cardiovascular Systems Completes Enrollment in ORBIT II Coronary Atherectomy Trial

Study evaluating effectiveness of orbital atherectomy technology in treating calcified coronary arteries

 

January 3, 2013

January 3, 2013 — Cardiovascular Systems Inc. (CSI) announced it has completed enrollment in its ORBIT II clinical trial, enrolling 443 patients. ORBIT II is evaluating the safety and effectiveness of the company’s orbital atherectomy technology in treating severely calcified coronary arteries. It is estimated that moderate to severe arterial calcium is present in nearly 40 percent of those treated annually for coronary artery disease (CAD). ORBIT II is the first premarket approval (PMA) trial designed to study these difficult-to-treat patients.

“Completing ORBIT II enrollment is a significant milestone in our efforts to secure a coronary indication to treat arterial calcium — a vastly underestimated problem in medicine today,” said David L. Martin, CSI president and CEO. “At TCT [in 2012], Dr. Philippe Genereux presented new data proving, with statistical significance, that patients with moderate to severe calcium were more likely to die and have major adverse coronary events, results Dr. Genereux described as ‘shocking.’”

The data presented at TCT 2012 in Miami by Genereux, director of the Angiographic Core Laboratory at the Cardiovascular Research Foundation (CRF), was from 14 randomized trials and included 11,651 treated with drug-eluting stents. While almost all of the studies were designed to exclude patients with moderate to severe calcium, nearly 21 percent of the patients enrolled actually had that level of calcium as confirmed by an independent angiographic core laboratory. Results from this patient subset showed statistically higher rates of death and MACE (major adverse cardiac events), including myocardial infarction, definitive stent thrombosis or ischemic target lesion revascularization, than patients with no or mild calcium.

“Despite advanced stent technology, moderate to severe calcification remains a real challenge for interventional cardiologists, and new therapeutic approaches are needed,” said Jeffrey Chambers, interventional cardiologist with Metropolitan Cardiovascular Consultants, Minneapolis, and principal investigator for the ORBIT II study. “Based on promising results in treating severely calcified coronary arteries in the ORBIT I study, CSI’s orbital technology may be well-suited for removing calcified plaque in coronary lesions. I look forward to seeing the results from ORBIT II and I’m hopeful that we will have a new therapy in the near future for these difficult-to-treat patients.”

CSI received U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) approval for the ORBIT II study in April 2010, and more than 45 U.S. medical centers enrolled patients. The primary endpoints of ORBIT II are based on a 30-day patient follow-up post-procedure. Of the 443 patients enrolled in ORBIT II, 343 were treated with CSI’s original pneumatic orbital atherectomy system (OAS) and 100 with the company’s new electric OAS. The new electric coronary OAS offers a simpler design that gives physicians complete control of device operation, with minimal setup time. CSI and the FDA agreed to a modular PMA submission.

To date, modules 1 (preclinical) and 2 (manufacturing/system quality) have been submitted to the agency and are currently under review. The company’s PMA will be final on submission of module 3, which includes ORBIT II clinical data and proposed labeling. CSI anticipates that this will occur in early 2013. A coronary application would open up a large, underserved market opportunity for CSI, estimated to exceed $1.5 billion annually.

For more information: www.csi360.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.